PTGX Q4 2024 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$171M+184.4% YoY

Gross Profit

$171M100.0% margin

Operating Income

$127M74.3% margin

Net Income

$132M77.2% margin

EPS (Diluted)

$1.98

QoQ Revenue Growth

+3550.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$745M

Total Liabilities

$69M

Stockholders' Equity

$675M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$171M	$60M	+184.4%
Gross Profit	$171M	$60M	+184.4%
Operating Income	$127M	$23M	+450.0%
Net Income	$132M	$27M	+381.7%

Revenue Segments

Development Services

$5M100%